No Data
Sirio Pharma Co., Ltd.'s (SZSE:300791) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sirio Pharma (300791.SZ) granted 1.511 million restricted stocks with a grant price of 13.27 yuan per share.
Sirio Pharma (300791.SZ) announced that on February 24, 2025, the company will grant restricted stock...
Sirio Pharma (300791.SZ): A preliminary global market layout has been established, covering major nutritional health food markets in China, the United States, Europe, and Asia-Pacific.
On February 19, Gelonghui reported that Sirio Pharma (300791.SZ) stated on the investor interaction platform that the company has preliminarily established a global market layout covering major nutritional health food regional markets in China, the United States, Europe, and Asia-Pacific. While stable growth is seen in the Chinese market, other global major markets are still in a rapid development phase. The company possesses a strong global competitive advantage and aims to replicate the successful experience from the Chinese market in overseas markets, indicating significant potential for future market growth. Currently, the impact of increased tariffs on the company's cross-border business is manageable, and the company is actively responding through means such as adjusting trade prices and formulating customer communication strategies.
Sirio Pharma (300791.SZ): Recently, development of smart formulas is underway, and integration with the Deepseek large model has been achieved.
On February 19, Glocker reported that Sirio Pharma (300791.SZ) stated on the investor interaction platform that the company is currently developing intelligent formula solutions and has integrated the Deepseek large model. Based on a deep understanding of the Industry pain points and the optimization of the R&D process, the integration of the DeepSeek large model will enable the creation of a unique intelligent formula design system. This will allow for the provision of scientifically sound and market trend-compliant formulas to Global clients in a shorter time frame, significantly enhancing R&D efficiency and customer satisfaction, and ultimately achieving a full-process intelligent upgrade from demand reception to solution output.
Director Yao Zhuangmin of Sirio Pharma (300791.SZ) has completed a shareholding of 0.1485 million shares.
Sirio Pharma (300791.SZ) issued an announcement that as of January 25, 2025, this shareholding plan has been ...
Sirio Pharma (300791.SZ): plans to launch a restricted stock incentive program of 1.8886 million shares.
On January 12, Glonghui announced that Sirio Pharma (300791.SZ) revealed its 2025 restricted stock incentive plan, proposing to grant a total of 1.8886 million shares of restricted stock to the incentive objects, which accounts for approximately 0.80% of the company's total share capital of 235.87288 million shares as of the announcement date. Among them, the initial grant of restricted stock is 1.511 million shares, accounting for about 0.64% of the company's total share capital of 235.87288 million shares as of the announcement date, and 80.01% of the total number of restricted stocks proposed for granting in this incentive plan; 0.3776 million shares are reserved.
Take Care Before Diving Into The Deep End On Sirio Pharma Co., Ltd. (SZSE:300791)
